Literature DB >> 35764787

Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: a review of clinical studies.

Farzana Y Zaman1, Suzanne G Orchard2, Andrew Haydon3, John R Zalcberg3,4.   

Abstract

Colorectal cancer (CRC) chemoprevention is an area of interest. Non-steroidal anti-inflammatory drugs (NSAIDs) are anti-inflammatory agents which have been identified as cancer chemoprevention agents given that inflammation is thought to contribute to tumorigenesis. Most studies have demonstrated that the NSAID, aspirin, plays a beneficial role in the prevention of CRC and colonic adenomas. Non-aspirin NSAIDs (NA-NSAIDs) have also been studied in CRC chemoprevention. There is increasing literature around their role in pre-cancerous polyp prevention and in decreasing CRC incidence and CRC-related outcomes in certain high-risk subgroups. However, the use of NA-NSAIDs may be accompanied by increased risks of toxicity. Further studies are required to establish the associations between concurrent aspirin and NA-NSAID use, and CRC-related outcomes.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID： 35764787     DOI： 10.1038/s41416-022-01882-8

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  35 in total

1.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.

Authors:  Peter M Rothwell; Michelle Wilson; Carl-Eric Elwin; Bo Norrving; Ale Algra; Charles P Warlow; Tom W Meade
Journal:  Lancet       Date:  2010-10-21       Impact factor: 79.321

2.  Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States).

Authors:  Joseph A Tangrea; Paul S Albert; Elaine Lanza; Karen Woodson; Don Corle; Marsha Hasson; Randall Burt; Bette Caan; Electra Paskett; Frank Iber; J Walter Kikendall; Peter Lance; Moshe Shike; Joel Weissfeld; Arthur Schatzkin
Journal:  Cancer Causes Control       Date:  2003-06       Impact factor: 2.506

Review 3.  NSAIDs inhibit tumorigenesis, but how?

Authors:  Evrim Gurpinar; William E Grizzle; Gary A Piazza
Journal:  Clin Cancer Res       Date:  2013-12-05       Impact factor: 12.531

Review 4.  Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Authors:  Alaa Rostom; Catherine Dubé; Gabriela Lewin; Alexander Tsertsvadze; Nicholas Barrowman; Catherine Code; Margaret Sampson; David Moher
Journal:  Ann Intern Med       Date:  2007-03-06       Impact factor: 25.391

5.  Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.

Authors:  Hideki Ishikawa; Michihiro Mutoh; Yasushi Sato; Hisashi Doyama; Masahiro Tajika; Shinji Tanaka; Takahiro Horimatsu; Yoji Takeuchi; Hiroshi Kashida; Jun Tashiro; Yasumasa Ezoe; Takeshi Nakajima; Hiroaki Ikematsu; Shinichiro Hori; Sadao Suzuki; Takahiro Otani; Tetsuji Takayama; Yoshio Ohda; Kanae Mure; Keiji Wakabayashi; Toshiyuki Sakai
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-04-02

6.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Authors:  Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

7.  Effect of Aspirin on Disability-free Survival in the Healthy Elderly.

Authors:  John J McNeil; Robyn L Woods; Mark R Nelson; Christopher M Reid; Brenda Kirpach; Rory Wolfe; Elsdon Storey; Raj C Shah; Jessica E Lockery; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Joanne Ryan; Barbara Radziszewska; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

8.  Effect of Aspirin on All-Cause Mortality in the Healthy Elderly.

Authors:  John J McNeil; Mark R Nelson; Robyn L Woods; Jessica E Lockery; Rory Wolfe; Christopher M Reid; Brenda Kirpach; Raj C Shah; Diane G Ives; Elsdon Storey; Joanne Ryan; Andrew M Tonkin; Anne B Newman; Jeff D Williamson; Karen L Margolis; Michael E Ernst; Walter P Abhayaratna; Nigel Stocks; Sharyn M Fitzgerald; Suzanne G Orchard; Ruth E Trevaks; Lawrence J Beilin; Geoffrey A Donnan; Peter Gibbs; Colin I Johnston; Barbara Radziszewska; Richard Grimm; Anne M Murray
Journal:  N Engl J Med       Date:  2018-09-16       Impact factor: 91.245

9.  Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019.

Authors:  C Bosetti; C Santucci; S Gallus; M Martinetti; C La Vecchia
Journal:  Ann Oncol       Date:  2020-04-01       Impact factor: 32.976

10.  Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial.

Authors:  John Burn; Harsh Sheth; Faye Elliott; Lynn Reed; Finlay Macrae; Jukka-Pekka Mecklin; Gabriela Möslein; Fiona E McRonald; Lucio Bertario; D Gareth Evans; Anne-Marie Gerdes; Judy W C Ho; Annika Lindblom; Patrick J Morrison; Jem Rashbass; Raj Ramesar; Toni Seppälä; Huw J W Thomas; Kirsi Pylvänäinen; Gillian M Borthwick; John C Mathers; D Timothy Bishop
Journal:  Lancet       Date:  2020-06-13       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.